Phase III trials assessing pembrolizumab, nivolumab, or atezolizumab compared to docetaxel as subsequent therapy for patients with metastatic NSCLC found there were no survival benefits for EGFR-mutant lung cancer patients. Here, EGFR is linked to non-small cell lung carcinoma.